196 related articles for article (PubMed ID: 10163487)
1. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process.
Aziz KJ; Sliva CA; Gutman SI
Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487
[No Abstract] [Full Text] [Related]
2. The evolution of substantial equivalence in FDA's premarket review of medical devices.
Goldberger BA
Food Drug Law J; 2001; 56(3):317-37. PubMed ID: 11944642
[No Abstract] [Full Text] [Related]
3. Delegations of authority and organization; Center for Devices and Radiological Health--FDA. Final rule.
Fed Regist; 1991 Oct; 56(197):51169-70. PubMed ID: 10115059
[TBL] [Abstract][Full Text] [Related]
4. Medical devices; exemptions from premarket notification; class II devices--FDA, Final rule.
Fed Regist; 1998 Nov; 63(212):59222-31. PubMed ID: 10187384
[TBL] [Abstract][Full Text] [Related]
5. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
[TBL] [Abstract][Full Text] [Related]
6. Gastroenterology-urology devices; effective date of requirement for premarket approval of the penile inflatable implant. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Apr; 65(71):19650-8. PubMed ID: 11010632
[TBL] [Abstract][Full Text] [Related]
7. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
Rulis AM; Levitt JA
Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
[TBL] [Abstract][Full Text] [Related]
8. Use and recognition of consensus standards in US premarket submissions.
Donawa ME
Med Device Technol; 1999 Mar; 10(2):13-7. PubMed ID: 10387610
[TBL] [Abstract][Full Text] [Related]
9. Medical devices; clinical chemistry and clinical toxicology devices; drug metabolizing enzyme genotyping system. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Mar; 70(46):11865-7. PubMed ID: 15762010
[TBL] [Abstract][Full Text] [Related]
10. Implications of FDA's proposal to include foreign marketing experience in the over-the-counter drug review process.
Pinco RG
Food Drug Law J; 1998; 53(1):105-22. PubMed ID: 11795327
[No Abstract] [Full Text] [Related]
11. FDA's proposed regulatory approach to regulation of hematopoietic stem/progenitor cell products.
Harvath L
Cytotherapy; 1999; 1(4):358-9. PubMed ID: 20440912
[No Abstract] [Full Text] [Related]
12. Food and Drug Administration (FDA)'s impact on laboratory performance: FDA's perspective.
Gutman S
Clin Chem; 1996 May; 42(5):786-9. PubMed ID: 8653915
[TBL] [Abstract][Full Text] [Related]
13. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
Grillo-López AJ
Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
[No Abstract] [Full Text] [Related]
14. Medical device safety: FDA's postmarket transformation initiative.
Schultz D
Food Drug Law J; 2007; 62(3):593-6. PubMed ID: 17915401
[No Abstract] [Full Text] [Related]
15. Medtronic, Inc.; premarket approval of the Interstim Sacral Nerve Stimulation (SNS) System--FDA. Notice.
Fed Regist; 1998 Jan; 63(19):4457. PubMed ID: 10177327
[TBL] [Abstract][Full Text] [Related]
16. Is FDA's medical device evaluation process overly complaisant to industry?
Margolis RE
Healthspan; 1992; 9(7):19-20. PubMed ID: 10121440
[No Abstract] [Full Text] [Related]
17. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
18. Medical devices; exemption from premarket notification and reserved devices; Class I--FDA. Proposed rule.
Fed Regist; 1998 Nov; 63(218):63222-53. PubMed ID: 10187398
[TBL] [Abstract][Full Text] [Related]
19. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
20. FDA's device inspection lacking. Two reports point to technology, staffing as key culprits.
Rhea S
Mod Healthc; 2008 Feb; 38(5):10-1. PubMed ID: 18318369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
